Form D · Biotechnology

Saliogen Therapeutics, Inc.

Cambridge, MA · CIK 0001845309

Offering snapshot reported Apr 18, 2022 · SEC filing

Reported sold
$132M
Offering amount: $132M
Investors reported
24
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 24, 2021
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$66.1M$132MDec 7, 2021: $74,099,666.00Dec 7, 2021Apr 18, 2022: $132,249,385.00Apr 18, 2022

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$74,099,666 → $132,249,385
  • Reported investors11 → 24

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 18, 2022Amendment$132,249,385$58,149,719vs Dec 7, 202124SEC filing
Dec 7, 2021Initial$74,099,666No comparison11SEC filing
Feb 18, 2021Initial$20,000,000No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-423901

Source: Form D, filed Apr 18, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Craig Gordon Director
Joseph Higgins Director, Executive
Sukumar Nagendran Director
Sean Stalfort Director
Raymond Tabibiazar Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
245 First Street 18 Th Floor
Cambridge, MA, 02142